在患有疹性流体角膜炎的患者体内进行CRISPR基因编辑
Anji Wei1, Di Yin2, Zimeng Zhai1
1Department of Ophthalmology and Visual Science, Eye, and ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Molecular therapy : the journal of the American Society of Gene Therapy
|September 2, 2023
概括
这项研究在体内探索了对疹性膜炎 (HSK) 的CRISPR基因疗法. 初步结果显示,这种简单疹病毒1 (HSV-1) 基因编辑方法在治疗HSK时是安全有效的.
科学领域:
- 眼科医生 眼科 眼科
- 基因治疗 基因治疗
- 分子生物学分子生物学
背景情况:
- 疹性流体角膜炎 (HSK) 是一种严重的角膜疾病,由简单疹病毒1 (HSV-1) 引起.
- 目前对HSK的治疗有局限性,而体内基因疗法提供了潜在的新治疗途径.
- 对HSK的体内CRISPR基因治疗的安全性和有效性在很大程度上仍未确立.
研究的目的:
- 评估体内CRISPR基因治疗的安全性和初步疗效,以重症HSK患者的HSV-1为向.
- 评估基因治疗后的CRISPR诱导的脱效应和全身不良事件.
主要方法:
- 进行了一项由研究者发起的,开放的,单臂的,非随机的干预试验.
- 在角膜移植期间,三名患有严重耐火性HSK的患者接受了一剂针对HSV-1的CRISPR配方.
- 使用GUIDE-seq检测CRISPR诱导的脱,并对患者进行不良事件和病毒持续性监测.
主要成果:
- 使用GUIDE-seq.没有观察到可检测的CRISPR诱导的目标外裂纹.
- 在平均18个月的随访期间,这三名患者中没有报告任何系统性不良事件.
- 在整个研究期间,疹简单病毒1 (HSV-1) 在所有患者中仍然无法检测到.
结论:
- 针对HSV-1基因组的体内基因编辑证明了HSK患者的可接受安全性.
- 这些初步临床数据表明,基于CRISPR的基因疗法是HSK的有前途的潜在治疗策略.
- 需要进一步的研究来证实这种方法的长期有效性和安全性.
相关概念视频
01:28CRISPR/Cas9 Genome Editing
49
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
49
01:59CRISPR
52.3K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
52.3K
02:31Homologous Recombination
50.6K
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
50.6K